Your browser doesn't support javascript.
loading
Screening for co-infections in patients with substance use disorders and severe bacterial infections.
Varley, Cara D; Conte, Michael; Streifel, Amber C; Winders, Bradie; Sikka, Monica K.
Afiliação
  • Varley CD; Division of Infectious Diseases, School of Medicine, Oregon Health & Science University, Portland, OR, USA.
  • Conte M; School of Public Health, Oregon Health & Science University-Portland State University, Portland, OR 97239, USA.
  • Streifel AC; Division of Infectious Diseases, School of Medicine, Oregon Health & Science University, Portland, OR, USA.
  • Winders B; Department of Pharmacy, Oregon Health & Science University, Portland, OR, USA.
  • Sikka MK; School of Public Health, Oregon Health & Science University -Portland State University, Portland, OR, USA.
Ther Adv Infect Dis ; 9: 20499361221132132, 2022.
Article em En | MEDLINE | ID: mdl-36277297
ABSTRACT

Background:

Patients with substance use disorders admitted for severe bacterial infection are in a prime position to be screened for important co-infections. However, data suggest that standard screening for co-infections in this population during hospital admission can vary in frequency and type of testing.

Methods:

We performed a retrospective review of patients to evaluate screening for co-infections during admission, followed by a case-control analysis to determine factors associated with lack of any screening.

Results:

We identified 280 patients with 320 eligible admissions. Most were male and Caucasian with unstable housing. Only 67 (23.9%) patients had a primary-care provider. About 89% (n = 250) of our cohort were screened for one or more co-infection during their first admission with one patient never screened despite subsequent admissions. Of those screened, the greatest proportion was HIV (219, 81.4% of those without history of HIV), HCV (94, 79.7% of those without a prior positive HCV antibody), syphilis (206, 73.6%), gonorrhea, and chlamydia (47, 16.8%) with new positive tests identified in 60 (21.4%) people. Screening for all five co-infections was only completed in 15 (14.0%) of the 107 patients who had screening indications. Overall, a high proportion of those screened had a new positive test, including three cases of neurosyphilis, highlighting the importance of screening and treatment initiation. One patient was prescribed HIV pre-exposure prophylaxis at discharge and only 37 (34.6%) of those eligible were referred for HCV treatment or follow-up. In multivariable case-control analysis, non-Medicaid insurance (OR 2.8, 95% CI 1.2-6.6, p = 0.02), use of only 1 substance (OR 2.9, 95% CI 1.3-6.5, p < 0.01), and no documented screening recommendations by the infectious disease team (OR 3.7, 95% CI 1.5-8.8, p < 0.01), were statistically significantly associated with lack of screening for any co-infection during hospital admission.

Conclusion:

Our data suggest additional interventions are needed to improve inpatient screening for co-infections in this population.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Idioma: En Revista: Ther Adv Infect Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Idioma: En Revista: Ther Adv Infect Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos